Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia.
10.3760/cma.j.issn.0253-2727.2023.11.005
- Author:
Li hong AN
1
;
De Feng ZHAO
1
;
Rui Feng HOU
1
;
Huan Huan GUAN
1
;
Hong YAN
1
;
Yue Hui LIN
1
;
Chun Rong TONG
1
;
Tong WU
1
;
Shuang You LIU
1
Author Information
1. Beijing GoBroad Boren Hospital, Beijing 100070, China.
- Publication Type:Journal Article
- Keywords:
CD22;
Inotuzumab ozogamicin;
Leukemia, B-cell, acute;
Relapsed/refractory
- MeSH:
Adult;
Humans;
Child;
Adolescent;
Inotuzumab Ozogamicin;
Receptors, Chimeric Antigen;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*;
Antibodies, Monoclonal;
Adaptor Proteins, Signal Transducing;
Antigens, CD19;
Chemical and Drug Induced Liver Injury
- From:
Chinese Journal of Hematology
2023;44(11):911-916
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen receptor (CAR) -T-cell therapy. Methods: Pediatric and adult patients who received two doses of inotuzumab and who were evaluated after inotuzumab treatment were included. Antibody infusions were performed between March 2020 and September 2022. All patients expressed CD22 antigen as detected by flow cytometry (>80% leukemic cells displaying CD22) before treatment. For adults, the maximum dosage per administration was 1 mg (with a total of two administrations). For children, the maximum dosage per administration was 0.85 mg/m(2) (no more than 1 mg/dose; total of two administrations). The total dosage administered to each patient was less than the standard dosage of 1.8 mg/m(2). Results: Twenty-one patients with R/R B-ALL were included, including five children (<18 years old) and sixteen adults. Seventeen patients presented with 5.0% -99.0% leukemic blasts in the bone marrow/peripheral blood or with extramedullary disease, and four patients were minimal residual disease (MRD) -positive. Fourteen patients underwent both CD19 and CD22 CAR-T-cell therapy, four underwent CD19 CAR-T-cell therapy, and three underwent blinatumomab therapy. Eleven patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). After inotuzumab treatment, 14 of 21 patients (66.7% ) achieved a complete response (CR, one was MRD-positive CR), and all four MRD-positive patients turned MRD-negative. Four of six patients who failed recent CD22 CAR-T-cell therapy achieved a CR after subsequent inotuzumab treatment. Seven patients (33.3% ) demonstrated no response. Grade 1-3 hepatotoxicity occurred in five patients (23.8% ), one child with no response experienced hepatic veno-occlusive disease (HVOD) during salvage transplantation and recovered completely. Conclusion: For patients with heavily treated R/R B-ALL, including those who had undergone allo-HSCT and CD19/CD22 CAR-T-cell therapy, the two-dose regimen of inotuzumab resulted in a CR rate of 66.7%, and the frequency of hepatotoxicity and HVOD was low.
